Havlíček L - Search Results

1

2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro.

Řezníčková E, Popa A, Gucký T, Zatloukal M, Havlíček L, Bazgier V, Berka K, Jorda R, Popa I, Nasereddin A, Jaffe CL, Kryštof V, Strnad M. Řezníčková E, et al. Among authors: havlicek l. Bioorg Med Chem Lett. 2015 Jun 1;25(11):2298-301. doi: 10.1016/j.bmcl.2015.04.030. Epub 2015 Apr 16. Bioorg Med Chem Lett. 2015. PMID: 25937014

2

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.

De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. De Azevedo WF, et al. Among authors: havlicek l. Eur J Biochem. 1997 Jan 15;243(1-2):518-26. doi: 10.1111/j.1432-1033.1997.0518a.x. Eur J Biochem. 1997. PMID: 9030780 Free article.

3

Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.

Havlícek L, Hanus J, Veselý J, Leclerc S, Meijer L, Shaw G, Strnad M. Havlícek L, et al. J Med Chem. 1997 Feb 14;40(4):408-12. doi: 10.1021/jm960666x. J Med Chem. 1997. PMID: 9046330

4

Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.

Otyepka M, Krystof V, Havlícek L, Siglerová V, Strnad M, Koca J. Otyepka M, et al. Among authors: havlicek l. J Med Chem. 2000 Jun 29;43(13):2506-13. doi: 10.1021/jm990506w. J Med Chem. 2000. PMID: 10891109

5

In vivo metabolism of 2,6,9-trisubstituted purine-derived cyclin-dependent kinase inhibitor bohemine in mice: glucosidation as the principal metabolic route.

Chmela Z, Veselý J, Lemr K, Rypka M, Hanus J, Havlícek L, Krystof V, Michnová L, Fuksová K, Lukes J. Chmela Z, et al. Among authors: havlicek l. Drug Metab Dispos. 2001 Mar;29(3):326-34. Drug Metab Dispos. 2001. PMID: 11181503

6

Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases.

Vermeulen K, Strnad M, Krystof V, Havlícek L, Van der Aa A, Lenjou M, Nijs G, Rodrigus I, Stockman B, van Onckelen H, Van Bockstaele DR, Berneman ZN. Vermeulen K, et al. Among authors: havlicek l. Leukemia. 2002 Mar;16(3):299-305. doi: 10.1038/sj.leu.2402378. Leukemia. 2002. PMID: 11896531

7

Synthesis and biological activity of olomoucine II.

Krystof V, Lenobel R, Havlícek L, Kuzma M, Strnad M. Krystof V, et al. Among authors: havlicek l. Bioorg Med Chem Lett. 2002 Nov 18;12(22):3283-6. doi: 10.1016/s0960-894x(02)00693-5. Bioorg Med Chem Lett. 2002. PMID: 12392733

8

Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors.

Moravcová D, Krystof V, Havlícek L, Moravec J, Lenobel R, Strnad M. Moravcová D, et al. Among authors: havlicek l. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2989-92. doi: 10.1016/s0960-894x(03)00631-0. Bioorg Med Chem Lett. 2003. PMID: 12941318

9

2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors.

Moravec J, Krystof V, Hanus J, Havlícek L, Moravcová D, Fuksová K, Kuzma M, Lenobel R, Otyepka M, Strnad M. Moravec J, et al. Among authors: havlicek l. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2993-6. doi: 10.1016/s0960-894x(03)00632-2. Bioorg Med Chem Lett. 2003. PMID: 12941319

10

8-Azapurines as new inhibitors of cyclin-dependent kinases.

Havlicek L, Fuksova K, Krystof V, Orsag M, Vojtesek B, Strnad M. Havlicek L, et al. Bioorg Med Chem. 2005 Sep 15;13(18):5399-407. doi: 10.1016/j.bmc.2005.06.007. Bioorg Med Chem. 2005. PMID: 15993080

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page